GLP-1 Drugs: An Honest Assessment
GLP-1 drugs are the most significant development in obesity and metabolic medicine in decades. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce levels of weight loss that were not achievable with medication before, and the clinical benefits go well beyond the scale. For the right patient, they are a legitimate and meaningful tool. They also come with real risks, particularly with long-term use, that are not getting enough attention in the enthusiasm around them. And they do not address the underlying metabolic dysfunction that made the weight problem develop in the first place.
This page covers what these drugs actually do, who they are most appropriate for, what the short and long-term risks look like, and where functional medicine fits alongside them.
The mechanism
GLP-1 stands for glucagon-like peptide-1, a hormone the gut naturally produces after eating. It signals the pancreas to release insulin, tells the liver to stop releasing glucose, and most importantly for weight loss, acts on the brain to reduce appetite and slow the rate at which the stomach empties. The result is that you feel full sooner, stay full longer, and think about food less. For people whose weight problem has a significant appetite and reward-system component, that effect is genuinely different from anything diet and exercise alone can produce.
The newer dual agonists like tirzepatide also act on GIP, a second gut hormone that amplifies the insulin response and appears to further enhance weight loss. Real-world data shows GLP-1 users lose around 7.7 percent of body weight on semaglutide and 12.4 percent on tirzepatide after one year. That is significant weight loss for a medication, though it is roughly half of what clinical trials showed, largely because of discontinuation rates in the real world.
The approvals have expanded well beyond weight loss and diabetes. In 2024 semaglutide became the first weight loss drug to also be approved for reducing the risk of serious cardiovascular events in patients with cardiovascular disease and obesity. In late 2024, tirzepatide became the first medication approved for sleep apnea. In August 2025, semaglutide became the first GLP-1 approved for metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease. The range of conditions these drugs benefit is genuinely broad and still expanding.
The right candidate
GLP-1 drugs are appropriate when the weight problem has reached a level where the health risks of staying at that weight outweigh the risks of the medication, and when other approaches have not produced adequate results. For someone who is significantly obese, has metabolic disease, and has genuinely failed at sustained lifestyle change, these drugs are a reasonable and supported intervention. The cardiovascular and liver benefits in particular mean that for some patients the risk-benefit calculation is clear.
They are less clearly appropriate for people with moderate weight concerns who have not yet tried a structured functional medicine approach to the underlying metabolic problem. For that group, addressing insulin resistance, thyroid function, sleep, and the specific dietary pattern through a personalized approach first is the better starting point, because it addresses the cause rather than the symptom and does not carry the risks that come with long-term drug use.
The short-term risks
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation. About 22 percent of semaglutide users and 16 percent of tirzepatide users stopped treatment within the first year, and GI side effects are the primary reason. These typically improve as the dose increases gradually, but for some people they are severe enough to make continuing impossible.
More serious but less common risks include pancreatitis, gallbladder disease, and gastroparesis, where stomach emptying slows so significantly that it becomes a medical problem in its own right. Anyone with a personal or family history of medullary thyroid cancer or MEN2 syndrome should not take these drugs, as they carry an increased risk in that population.
The longer-term picture
The long-term safety picture is still being written, because widespread use is relatively recent. But several patterns are already clear enough to take seriously.
Muscle loss. Studies indicate that up to 40 percent of weight lost on some GLP-1 medications can be lean muscle rather than fat tissue. Loss of lean muscle mass and bone density with significant weight reduction have important implications for long-term health outcomes, particularly in older adults. Muscle loss lowers metabolic rate, reduces physical capacity, and makes weight maintenance harder when the drug is eventually stopped. This is not a minor side effect. It is a significant long-term consequence that is not adequately communicated to most patients starting these drugs.
Bone density. Rapid weight loss with GLP-1 medications can modestly lower bone density, especially at the hip, driven by reduced mechanical loading, muscle loss, and inadequate calcium, vitamin D, and protein rather than a direct drug effect. New research from the 2026 AAOS meeting found GLP-1 users had significantly higher rates of osteoporosis and osteomalacia compared to non-users. For older adults and postmenopausal women already at higher baseline risk, this is a meaningful concern.
Nutrient deficiencies. Micronutrient deficiencies remain a concern and may necessitate monitoring and supplementation. When food intake drops significantly, so does the intake of the nutrients that food was delivering. Key nutrients at risk include calcium, vitamin D, B vitamins, iron, and protein. These deficiencies do not produce obvious symptoms in the short term but have real consequences over time.
Weight regain after stopping. Studies show that without ongoing medication, most patients regain 75 to 90 percent of lost weight within two years. This is the most important long-term consideration for people starting these drugs. The weight loss is real while the drug is working. The question of what happens when it stops, whether from cost, side effects, or choice, is one that needs to be part of the conversation before starting.
The FM role
If you are considering a GLP-1 drug, functional medicine is a useful first step, because it gives you a complete picture of the metabolic problem you are dealing with and what the most appropriate intervention looks like at this stage. For some people, addressing insulin resistance, thyroid function, sleep, and dietary pattern through a structured approach is enough to produce meaningful and lasting results without medication. For others, the metabolic situation has progressed far enough that a GLP-1 drug is the right tool, and a functional medicine foundation makes that drug work better and more safely.
If you are already on a GLP-1 drug, functional medicine has four specific things to offer.
Muscle preservation. Resistance exercise and adequate protein are the primary tools for preventing muscle loss during rapid weight loss. We help you build a specific exercise and nutrition plan around this, not a generic recommendation to exercise more. The research is clear that without deliberate effort to preserve muscle, a significant portion of weight lost on these drugs will be lean tissue.
Nutrient monitoring and support. We monitor the nutrient levels most at risk from reduced food intake: vitamin D, B12, iron, magnesium, calcium, and protein adequacy. Deficiencies in these areas are common and addressable before they become symptomatic.
Gut support for side effects. The GI side effects that cause most people to stop these drugs, nausea, motility problems, and digestive disruption, have a functional medicine component. Supporting gut motility, digestive enzyme production, and gut bacterial balance reduces the severity of these side effects for many patients and improves tolerability.
Addressing the underlying metabolic dysfunction. A GLP-1 drug reduces appetite and improves insulin signaling while you are taking it. It does not address what caused the insulin resistance, the thyroid problem, the inflammatory pattern, or the sleep disruption that contributed to the metabolic situation in the first place. Working on those causes while the drug is doing its job gives you the best chance of maintaining results if you eventually stop, because the metabolic ground has shifted rather than just the symptom being suppressed.
If you are on a GLP-1 drug and want support with muscle preservation, nutrient monitoring, gut side effects, or addressing the underlying metabolic picture, or if you want a complete metabolic workup before deciding whether medication is the right first step, we can help. Read more about our functional medicine approach.
Schedule a consultation or call 704-663-2010.
Serving Mooresville and the Lake Norman area, including Davidson, Cornelius, Huntersville, Troutman, and Statesville.
